Results 71 to 80 of about 3,342 (167)
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa +25 more
wiley +1 more source
Background. HCV and HBV present a great challenge in the management of β-thalassemia patients. Objective. The present study aimed to determine the prevalence of both HBV and HCV in multitransfused-dependent β-thalassemia patients in northern West Bank ...
Kamal Dumaidi +3 more
doaj +1 more source
Opposing roles of acid phosphatase 1 (ACP1) and ACP3 in prostate cancer progression
Objectives To evaluate the roles of intracellular acid phosphatase 1 (ACP1) and ACP3 expression as biomarkers of prostate cancer progression through a systematic review and meta‐analysis assessing associations with disease presence, tumour aggressiveness, and patient prognosis.
Alessandra V. de S. Faria +3 more
wiley +1 more source
Abstract Transmembrane mucin 1 (tMUC1) provides oral mucosal barrier against pathogens. The invasion of oncopathogenic microbes can promote cancerous proliferation of cells via inflammatory responses, abnormal cellular signaling, angiogenesis, anti‐adhesion, and tumorigenesis.
Lauriina Soiniemi +4 more
wiley +1 more source
Bringing Gene Therapy Into Real World Clinical Practice
ABSTRACT Introduction Adeno‐associated virus (AAV)‐based gene therapy for haemophilia has shifted therapeutic paradigms by enabling hepatic gene transfer, restoring endogenous clotting factor expression, and reducing reliance on conventional prophylactic treatments. Two products, valoctocogene roxaparvovec (haemophilia A) and etranacogene dezaparvovec (
Wolfgang Miesbach +2 more
wiley +1 more source
ABSTRACT Background and Aims Patients with chronic hepatitis C and advanced fibrosis remain at substantial risk of hepatocellular carcinoma (HCC) and non‐liver–related death even after sustained virological response (SVR) to direct‐acting antivirals (DAA).
Daisuke Sakon +19 more
wiley +1 more source
Results for anti-HCV and HCV RNA between the years of 2004 and 2005 in Southeast Turkey (Diyarbakır)
Background: This study evaluates and presents the results for anti-hepatitis C virus (HCV) and HCV RNA obtained from sera sent to the Microbiology Laboratory of Dicle University Faculty of Medicine, the largest health center in the region (Diyarbakir ...
Ozekinci Tuncer and Atmaca Selahattin
doaj
Patients with severe ICI‐induced liver injury are commonly treated with corticosteroids, but the optimal tapering strategy remains uncertain. In this study, a gradual corticosteroid tapering strategy based partly on Japanese clinical practice for autoimmune hepatitis was associated with a low rate of relapse and enabled many patients to safely resume ...
Naoto Soma +7 more
wiley +1 more source
Objectives: Regular blood transfusions are essential for patients with thalassaemia major. However, infections with hepatotropic viruses remain a major concern. The objective of this study was to evaluate the prevalence and characteristics of hepatitis C
Khalid Al-Naamani +4 more
doaj +2 more sources

